Mattia Consalvo, Luongo Livio, Innamorato Massimo, Melis Luca, Sofia Michele, Zappi Lucia, Puntillo Filomena
Department of Medical and Surgical Sciences and Biotechnologies, Faculty of Pharmacy and Medicine, "Sapienza" University of Rome, Rome, Italy.
Anesthesia, Intensive Care and Pain Unit, ICOT-Polo Pontino, Latina, Italy.
J Pain Res. 2021 Oct 11;14:3193-3206. doi: 10.2147/JPR.S314206. eCollection 2021.
The aim of the present work was to evaluate the knowledge and prescriptive habits of clinicians involved in the management of chronic non cancer pain (CNCP), with a special focus on the use of opioids.
A Delphi method was used. A Board of specialists elaborated and discussed a series of statements, based on available literature and personal clinical expertise, about particularly controversial topics on pain pathophysiology and treatment. A Panel of experts in the field of pain management, selected by the Board, was invited to vote the proposed statements, indicating the level of agreement on a 5-point Likert scale (1: strongly disagree; 2: disagree; 3: partially agree; 4: agree; 5: strongly agree). The threshold for consensus was set at minimum 66.6% of the number of respondents with a level of agreement ≥4 (Agree or Strongly agree).
The Board included 5 pain therapists, 1 pharmacologist and 1 methodology expert and drew up a total of 36 statements (for a total of 40 requested answers)". A total of 100 clinicians were included in the Expert Panel. Respondents were 89 (89%). Consensus was achieved for 32 out of 40 answers. Most of the lack of consensus was recorded for statements regarding opioids use, and resulted from a low level of agreement (3 on the Likert scale), suggesting a neutral position deriving from a lack of knowledge rather than a strong contrary opinion.
Most of the proposed items reached consensus, suggesting a generally homogeneous approach to CNCP management. However, the lack of consensus recorded for several items regarding opioid use confirms the need to fill important gaps in the knowledge of available agents. A clear explanation of the peculiar pharmacological properties of drugs associated with potential clinical advantages (such as buprenorphine) will help optimize pain treatment in both primary care and hospital settings and improving pain control in CNCP patients.
本研究旨在评估参与慢性非癌性疼痛(CNCP)管理的临床医生的知识和处方习惯,特别关注阿片类药物的使用。
采用德尔菲法。一个专家委员会根据现有文献和个人临床专业知识,精心制定并讨论了一系列关于疼痛病理生理学和治疗中特别有争议话题的陈述。由该委员会挑选的疼痛管理领域专家小组被邀请对提出的陈述进行投票,在5点李克特量表(1:强烈不同意;2:不同意;3:部分同意;4:同意;5:强烈同意)上表明同意程度。共识阈值设定为同意程度≥4(同意或强烈同意)的受访者数量至少达到66.6%。
专家委员会包括5名疼痛治疗师、1名药理学家和1名方法学专家,共拟定了36条陈述(共40个所需答案)。专家小组共纳入100名临床医生。89名(89%)受访者进行了回复。40个答案中有32个达成了共识。关于阿片类药物使用的陈述大多未达成共识,原因是同意程度较低(李克特量表上为3),这表明是由于知识不足导致的中立立场,而非强烈的反对意见。
大多数提议项目达成了共识,表明对CNCP管理通常采用同质化方法。然而,关于阿片类药物使用的几个项目未达成共识,这证实了需要填补现有药物知识方面的重要空白。对与潜在临床优势相关药物(如丁丙诺啡)的特殊药理特性进行清晰解释,将有助于在初级保健和医院环境中优化疼痛治疗,并改善CNCP患者的疼痛控制。